Compare GSK plc (GSK) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Shell PLC — how do they compare? GSK plc trades at $50.62 (market cap $102.60B), while Shell PLC trades at $90.27 (market cap $250.44B). The key difference: Shell PLC is far larger — about 2.4× GSK plc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | SHEL | |
|---|---|---|
Market Cap | $102.60B | $250.44B |
Sector | Health | Energy |
52-Week High | $61.18 | $94.15 |
52-Week Low | $38.22 | $70.31 |
Enterprise Value | $123.04B | $292.14B |
Dividend Yield | 3.57% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Shell (SHEL) trades at $89.95, up 1.64% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The stock shows attractive valuation with a P/E of 10.01 and P/S of 0.88, supported by robust cash flow and a 14.35% ROE. Recent news highlights oil price gains boosting energy stocks and Shell's strategic divestments in renewables.
Outlook is positive with a $103.60 consensus price target and 69% buy ratings, though risks include commodity volatility and regulatory pressures. Earnings growth and debt reduction provide upside, while geopolitical tensions and energy transition uncertainties remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
